|
http://www.medasorb.com/default.htm MedaSorb Technologies Corporation Improves Balance Sheet Tuesday February 3, 2009, 12:24 pm EST MONMOUTH JUNCTION, NJ--(MARKET WIRE)--Feb 3, 2009 -- MedaSorb Technologies Corporation (OTC BB:MSBT.OB - News) and its wholly-owned subsidiary, CytoSorbents, Inc., announced that it was approved to participate in the New Jersey Emerging Technology and Biotechnology Financial Assistance Program and sold its net operating loss, netting approximately $248,000 to the Company. This is in addition to the $840,000 raised in the second close of the Series B financing in August 2008, bringing the total amount of capital raised by the Company to $5.5 million over the past 7 months. "This further bolsters our balance sheet to facilitate the completion of our European Sepsis Trial -- evaluating the treatment of patients with severe sepsis and respiratory failure with our CytoSorb(TM) resin cartridge," commented Dr. Phillip Chan, CEO. "Severe sepsis, often called 'overwhelming infection,' is so prevalent that most people unfortunately know someone who has died from this terrible disease. CytoSorbents hopes to significantly impact the outcome of sepsis with its unique treatment approach." |
|
| aus der Diskussion: | Diskussion zu CytoSorbents Corporation |
| Autor (Datum des Eintrages): | BrauchGeld (20.05.09 17:35:07) |
| Beitrag: | 2 von 4,237 (ID:37220865) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |